==== Front ScientificWorldJournal ScientificWorldJournal tswj The Scientific World Journal 2356-6140 1537-744X Hindawi 10.1155/2023/1124606 Research Article Evaluation of Antidiabetic and Antioxidant Activities of Fruit Pulp Extracts of Cucurbita moschata Duchesne and Cucurbita maxima Duchesne https://orcid.org/0000-0001-6060-1738 Suwannapong Apinya https://orcid.org/0000-0002-8882-2724 Talubmook Chusri https://orcid.org/0000-0001-8821-2267 Promprom Wilawan wipromprom@gmail.com Department of Biology, Faculty of Science, Mahasarakham University, Maha Sarakham 44150, Thailand Academic Editor: Ahmad Mansour 2023 22 6 2023 2023 112460612 10 2022 11 6 2023 12 6 2023 Copyright © 2023 Apinya Suwannapong et al. 2023 https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective To evaluate and compare the antidiabetic and antioxidant activities of fruit pulp extracts from Cucurbita moschata (PCMOS) and Cucurbita maxima (PCMAX). Methods The antidiabetic activity was carried out in vivo by orally and daily giving the extracts at a dose of 500 mg/kg·b.w. to the streptozotocin-induced diabetic male albino Wistar rats for six weeks. After the period of administration, blood glucose levels, body weight, serum insulin, morphology of islets of Langerhans, biochemical parameters, and haematological values of the rats were determined. Meanwhile, the antioxidant activity was carried out in vitro by determination of total phenolic and flavonoid contents, DPPH radical scavenging activity, and ferric reducing antioxidant power. Results PCMAX significantly (p < 0.05) reduced blood glucose levels but increased the body weight, serum insulin levels, size and number of islets of Langerhans, and β-cell number of the treated diabetic rats more than PCMOS did. However, they did not alter biochemical parameters and haematological values of the treated diabetic rats. PCMAX possessed total phenolic and flavonoid contents and showed DPPH scavenging and FRAP reducing antioxidant power more significantly (p < 0.05) than PCMOS. Conclusions According to the obtained results, it is indicated that PCMOS and PCMAX possess antidiabetic and antioxidant activities. PCMAX possesses more potent antidiabetic and antioxidant activities than PCMOS. These are probably due to PCMAX providing polysaccharide and total phenolic and flavonoid contents more than PCMOS. Mahasarakham UniversityScience Achievement Scholarship of ThailandNational Research Council of Thailand ==== Body pmc1. Introduction Diabetes mellitus (DM) is a severe metabolic disease that significantly impacts the health, quality of life, and life expectancy of patients, as well as the healthcare system [1]. It is a chronic carbohydrate, fat, and protein metabolism disorder characterized by high blood glucose levels resulting from the absence of insulin or insulin resistance [2, 3]. DM can cause substantial morbidity, mortality, and long-term complications [4]. The prevalence of DM will increase to 370 million or more by 2030 [5]. There is an urgent need for therapeutic agents to treat DM with fewer side effects. Synthetic antidiabetic agents often possess serious side effects. As the availability of antidiabetic agents in developing countries is limited, alternative approaches for treating diabetes using suitable antidiabetic agents from food sources are therefore being examined. Food has been documented to have antidiabetic properties, including cucurbits in the Cucurbitaceae family [6]. Pumpkin, a vegetable, belongs to the Cucurbitaceae. This family comprises about 130 genera with 800 species and can be cultivated worldwide [7, 8]. Pumpkin has been used in traditional systems of medicine. It exhibits various pharmacological actions, such as antidiabetic, anticancer, antihypertension, antioxidant, anti-inflammation, antihyperlipidemic, antimicrobial, and immunomodulation [9]. Its fruits are a valuable part of the plant with a high nutritional value [10] and are a good source of polyphenols [11], vitamin A, iron, phosphorus, calcium, and polysaccharides. Most bioactive chemicals are concentrated in its fruits [12]. C. moschata is a potential source of many antioxidant effects, such as carotenoids and polyphenols. Its fruit pulp is rich in many essential human and animal body compounds, such as amino acids, carbohydrates, polysaccharides, vitamins, and minerals [13, 14]. Its fruits are also rich in polysaccharides that show strong hypoglycemic and antidiabetic effects [15–18]. A previous investigation showed that pumpkin is reported to reduce blood glucose in type 2 diabetic patients [19]. C. maxima is traditionally used in Mexico, China, and India for its hypoglycemic effect helpful in controlling blood glucose [20, 21]. It has high potential for antidiabetic activity and can decrease high blood glucose levels in critically ill diabetic patients [21]. Its fruit juice, hydroalcoholic extract [20], fruit flesh powder [22], alcoholic seed extract [23], aqueous extract [24], and methanol extract [25, 26] significantly decreased hyperglycemia in STZ-induced diabetic rats. Studies in animal and human models revealed that treatment with some cucurbits exhibited hypoglycemic effects and stimulated β-cell regeneration. At least one of the bioactive components which produced these effects was a polysaccharide [18]. Crude polysaccharides from pumpkin showed hypoglycemic activity in alloxan-induced diabetic rats [27]. Moreover, the pumpkin polysaccharide extract gave excellent healing potential in alloxan-induced diabetic male ICR mice [28] and alloxan-induced diabetic rabbits [17]. It is thought that these effects may have been due to the antioxidant nature of the polysaccharide protecting pancreatic β cells [29], resulting in a reduced need for insulin in diabetic patients [30]. Pumpkin has been reported to be a source of antioxidants such as polyphenols and carotenoids [31], acidic polysaccharide extracted from pumpkin [32], water-soluble polysaccharide fraction from fruits of C. maxima [33], fractions of water-soluble polysaccharide from the fruit of pumpkin [29], methanol extract from aerial parts of C. maxima [25], mature fruits of C. moschata [34], methanolic and aqueous extracts of C. moschata fruits [35], methanolic extract of leaves of C. maxima [10], ethanol extracts of C. moschata and C. maxima [36], leaf extract of C. moschata [37], C. moschata flour [38], and flesh of C. maxima [39]. To elucidate the underlying mechanisms that could lead to the antidiabetic and antioxidant activities of the pumpkin, the present study was therefore undertaken to investigate the antidiabetic activity of extracts from the fruit pulp of C. moschata and C. maxima in STZ-induced diabetic rats and the antioxidant activity by DPPH scavenging and FRAP assays and evaluate the total phenolic and flavonoid contents. The results might help identify novel and relevant natural resources for the treatment of diabetes. 2. Materials and Methods 2.1. Plant Materials Fresh mature fruits of C. moschata purchased from local gardens in Yasothon Province and C. maxima from a local market in Khon Kaen Province, Northeastern Thailand, were used in this study. The pumpkin fruit specimens were identified and authenticated by a botanist in the Department of Biology, Faculty of Science, Mahasarakham University, Thailand. Voucher plant specimens (MSU-SAMOS and MSU-SAMAX) have been deposited at the same department. 2.2. Preparation of Extracts The plant fruits were washed, and the fruit pulp was cut into small pieces, dried in a hot air oven at 50°C. The dried samples were powdered using an electric grinder. The plant powder was extracted according to the procedure by Quanhong et al. [29] with slight modifications. The plant powder was separately suspended in distilled water at a ratio of 1 g powder:20 mL of distilled water, stirred in a water bath at 45°C for 16 h, and cooled and centrifuged at 4,800 rpm for 25 min. The supernatant was collected, concentrated to a quarter of the original volume by evaporating under reduced pressure at 45°C, and filtered to remove any residues. Three volumes of 95% ethanol were added to the filtrate to induce precipitation. The precipitated preparations were centrifuged at 4,800 rpm for 25 min. The pellet was collected, washed with ethanol, and freeze-dried. Each preparation was dissolved in distilled water (1 g/50 mL), dialysed against distilled water at 4°C for 72 h, and then freeze-dried. The yields of extracts from C. moschata (PCMOS) and C. maxima (PCMAX) were 1.15 and 1.10% DW, respectively. Because the active ingredient found in pumpkin has been reported to be polysaccharide [15], the PCMOS and PCMAX extracts were assayed for polysaccharides using the phenol-sulfuric acid method. A 2 mL aliquot of the extract suspension was mixed with 1 mL of 5% aqueous solution of phenol in a test tube. Five mL of concentrated sulfuric acid was added rapidly to the mixture. After allowing it to stand for 10 min, the mixture was mixed thoroughly using a vortex mixer for 30 s and placed for 20 min in a water bath at room temperature (27°C) for colour development. Light absorption at 490 nm was recorded with a spectrophotometer. The percentage polysaccharide in PCMOS and PCMAX was calculated and found to be 33.41 and 36.99%, respectively. 2.3. Determination of Antidiabetic Activity 2.3.1. Experimental Animals Male albino Wistar rats (200–250 g body weight) from the Laboratory Animal Centre, Suranaree University of Technology, Thailand, were used to assess antidiabetic activity. The rats were housed at room temperature (23 ± 2°C) and relative humidity (50–55%), and exposed to a 12 h day-night cycle, and fed with a standard commercial pellet diet and water ad libitum. Animals were maintained in accordance with the guidelines of the Committee Care and Use of Laboratory Animal Resource, National Research Council Thailand, and the advice of the Institutional Animal Care and Use Committee, Mahasarakham University, Thailand, with approval number IACUC/MSU 0020/2017. 2.3.2. Induction of Diabetes The overnight fasting rats were induced to be diabetic by a single intraperitoneal injection of 65 mg/kg·b.w. streptozotocin (STZ, Sigma Chemicals, St. Louis, MO), freshly prepared in 20 mM citrate buffer pH 4.5. After STZ injection, the rats were provided with 2% sucrose in drinking water for 48 h to alleviate discomfort after initiating the hypoglycemic phase. After 3 days of diabetic induction, fasting blood glucose (FBG) of each rat was assessed by using a glucometer (Accu-Check, Roche, Manheim, Germany). The rats with FBG at or above 126 mg/dL were considered to be diabetic and employed in the study [40]. 2.3.3. Experimental Design A total of 30 rats, 6 normal rats and 24 diabetic rats, were used. The rats were divided into five groups with six rats in each. Group I: normal rats were treated with 0.5% Tween 80 (normal controls). Group II: diabetic rats were treated with 0.5% Tween 80 (diabetic controls). Groups III, IV, and V: diabetic rats were treated with PCMOS 500 mg/kg·b.w., PCMAX 500 mg/kg·b.w., and glibenclamide 0.5 mg/kg·b.w., respectively. PCMOS and PCMAX were suspended in 0.5% Tween 80 and administered orally to the rats using an orogastric tube. The volume of administration was 10 mL/kg·b.w [41]. The oral administration of PCMOS, PCMAX, and the standard drug, glibenclamide, was carried out once a day for a period of six weeks. Body weight, fasting blood glucose, haematological values, serum insulin levels, biochemical parameters for lipid profiles, renal and hepatic functions, and pancreatic histological observation of the rats were determined. 2.4. Determination of Body Weight and Fasting Blood Glucose Before the commencement of the experiments, body weight and fasting blood glucose levels of all rats were monitored. After the administration of PCMOS, PCMAX, and glibenclamide, the body weight and fasting blood glucose levels were measured weekly for 6 weeks. The fasting blood glucose level was evaluated from a drop of fasting blood drawn by the tail prick method using a glucometer (Accu-Check, Roche, Manheim, Germany). 2.5. Determination of Haematological Values At the end of the experiments, the rats were made to fast overnight and were sacrificed under ether anesthesia. Blood samples were collected from the rat hearts by cardiac puncture and heparinized. The heparinized blood was used for the determination of haematological values, including white blood cells (WBCs), red blood cells (RBCs), hemoglobin (Hb), hematocrit (Hct), neutrophils (Neu), lymphocytes (Lym), monocytes (Mono), and platelets (Plt) by using an automatic blood chemical analyzer (BT 2000 plus, Germany). 2.6. Determination of Serum Insulin Levels The blood sample collected from each rat heart was centrifuged to separate blood serum. The insulin levels in the serum were determined using a radio immune assay kit (MP Biomedicals; Orangeburg, NY, USA) and detected using an automatic gamma counter (Wallac 1470 Wizard; Perkin Elmer Instrument; Überlingen, Germany). 2.7. Estimation of Biochemical Parameters The biochemical parameters in the rat serum, including total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, total protein, blood urea nitrogen (BUN), creatinine (Crea), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP), were estimated following enzyme colorimetric methods using automate SYNCHRON LX20 PRO. 2.8. Histological Observation After scarification, the rat pancreas was removed immediately and prepared for histological observation. The pancreas was washed with normal saline, fixed in 10% formaldehyde, embedded in paraffin, and sectioned using a rotary microtome. Slides of the sections of approximately 5 microns were routinely stained with hematoxylin and eosin (H&E) and were qualitatively (morphological) and quantitatively (morphometric) analyzed according to Berraaouan et al. [42] with some modifications. 2.9. Determination of Antioxidant Activity The antioxidant activity of PCMOS and PCMAX was determined by using the 2, 2- diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging assay and ferric reducing antioxidant power (FRAP) assay. As antioxidant potential of many plants is mainly due to phenolic components, total phenolic and flavonoid contents in PCMOS and PCMAX were also investigated. 2.10. DPPH Free Radical Scavenging Assay The antioxidant activity of PCMOS and PCMAX using the DPPH assay was assessed according to the method by Nakornriab and Krasaetep [43] with suitable modifications. PCMOS and ECMAX at the concentrations of 0.1, 0.2, 0.4, 0.6, 0.8, and 1 mg/mL were mixed with 3.0 mL of 0.1 mM DPPH solution. The mixture was shaken and incubated at 37°C for 30 min in the dark. Absorbance at 517 nm was recorded using a spectrophotometer. Ascorbic acid was used as a reference reagent. The DPPH radical scavenging assay was carried out with three replicates. Percentage inhibition of DPPH radicals was calculated using the following equation:(1) % inhibition=1−absorbance of the solution with extractsabsorbance of the solution without extracts×100. IC 50 of PCMOS, PCMAX, and ascorbic acid was estimated from plots of % inhibition vs. concentration. 2.11. Ferric Reducing Antioxidant Power (FRAP) Assay The FRAP assay was performed using a modified method described by Zolfaghari et al. [44]. PCMOS or PCMAX solution (100 µL of 10 mg/mL) was mixed with 3 mL of FRAP solution (300 mM acetate buffer, pH 3.6, 10 mM/L TPTZ in 40 mM/L HCl, and 20 mM/L FeCl3 anhydrous). The working FRAP reagent was prepared freshly by mixing acetate buffer, TPTZ solution, and FeCl3 anhydrous in the ratio of 10 : 1 : 1. The prepared FRAP solution was incubated at 37°C for 4 min. The absorbance was then measured at 593 nm using a UV-visible spectrophotometer. The results were expressed as millimolar ferrous sulphate per gram of dry weight (mM Fe (II)/g DW). 2.12. Determination of Total Phenolic Content The total phenolic content in PCMOS and PCMAX was determined calorimetrically using the Folin–Ciocalteu reagent according to the modified method by Bonoli et al. [45]. 50 µL of the extracts (10 mg/mL) was mixed with 1.5 mL of the 10% Folin–Ciocalteu reagent (diluted 10 fold with distilled water). The mixed solution was incubated at room temperature for 15 min, and then, 1.5 mL of 10% (w/v) sodium carbonate solution was added. The mixture was shaken and incubated again at room temperature for 15 min. Gallic acid was used as a standard agent. The absorbance of all samples was measured at 750 nm using a UV-visible spectrophotometer. Total phenolic content was calculated by comparison to a gallic acid standard curve and expressed as mg gallic acid equivalent/g (mg GAE)/g. 2.13. Determination of Total Flavonoid Content The amount of total flavonoid content of PCMOS and PCMAX was determined according to the modified method by Prasad et al. [46]. PCMOS or PCMAX (250 µL of 10 mg/mL) was mixed with 1.25 mL of deionized water and 75 µL of 5% sodium nitrite (NaNO2) solution and allowed to stand for 5 min at room temperature. Aluminium chloride (AlCl3) (150 µL of 10% solution) was added to the mixture and allowed to react for 6 min at room temperature. Then, 500 µL of 1 M sodium hydroxide (NaOH) and 775 µL of distilled water were added to the mixture. The absorbance of all samples was immediately measured at 510 nm using a UV-visible spectrophotometer. The samples were assayed in triplicate. The amount of total flavonoid content was calculated using a catechin calibration curve and expressed in mgCE/g. 2.14. Data Analysis Data were expressed as the mean ± standard error of mean (SEM). The significant difference in data between different groups was compared using one-way analysis of variance (ANOVA) followed by Duncan's test. p < 0.05 was considered to indicate a significant difference. 3. Results 3.1. Determination of Antidiabetic Activity The results of body weight, haematological values, blood glucose levels, serum insulin levels, number of β cells, size of islets of Langerhans, biochemical parameters including lipid profiles, and renal and hepatic function parameters of normal controls, diabetic controls, and diabetic rats treated with PCMOS, PCMAX, and glibenclamide are presented in Tables 1–4 and Figure 1, respectively. 3.2. Body Weight At the initial stage, the body weight of the rats was not different. However, at the end of the experiments, the body weight of the diabetic controls decreased significantly (p < 0.05) when compared to that of the normal controls (301.56 ± 11.12 vs. 361.33 ± 10.95 g). It increased significantly (p < 0.05) in the diabetic rats treated with PCMOS (354.16 ± 7.44 g) and PCMAX (359.66 ± 7.74 g) compared to that in the diabetic controls and in the diabetic rats treated with glibenclamide (354.16 ± 8.96 g). 3.3. Fasting Blood Glucose Levels At the initial stage, fasting blood glucose of the diabetic rats was significantly higher (p < 0.05) than that of the normal controls. At the end of the experiments, the fasting blood glucose level of the diabetic controls (186.66 ± 15.70 mg/dL) increased significantly (p < 0.05) compared to that in the normal controls (83.07 ± 11.47 mg/dl). In contrast, it reduced significantly (p < 0.05) in the diabetic rats treated with PCMOS (102.16 ± 11.20 mg/dl) and PCMAX (96.00 ± 13.05 mg/dl) compared to that in the diabetic controls, but it was not different from that in the diabetic rats treated with glibenclamide (96.66 ± 12.32 mg/dL). 3.4. Haematological Values The determination of haematological values revealed that white blood cells (WBCs), red blood cells (RBCs), hemoglobin (Hb), hematocrit (Hct), neutrophils (Neu), lymphocytes (Lym), and monocytes (Mono) of all groups of rats were not different. However, platelet counts of the diabetic controls (9.03 ± 1.12×103 cells/mm3), diabetic rats treated with PCMOS (9.26 ± 1.23×103 cells/mm3), and diabetic rats treated with glibenclamide (8.85 ± 1.51 × 103 cells/mm3) increased slightly (7.6.45 ± 2.26 × 103 cell/mm3) and increased significantly (p < 0.05) in the diabetic rats treated with PCMAX (9.69 ± 1.34 × 103 cells/mm3) compared to those in the normal controls. 3.5. Serum Insulin Level The serum insulin level of the diabetic controls (12.14 ± 0.34 µIU/mL) decreased significantly (p < 0.05) compared with that of the normal controls (23.88 ± 1.38 µIU/mL). In contrast, it increased significantly (p < 0.05) in the diabetic rats treated with PCMAX (16.64 ± 3.20 µIU/mL) and increased slightly in the diabetic rats treated with PCMOS (13.00 ± 0.20 µIU/mL). However, it was less than that in the diabetic rats treated with glibenclamide (24.80 ± 0.50 µIU/ml) which was close to that in the normal controls. 3.6. Biochemical Parameters The lipid profiles, including total cholesterol (TC), triglycerides (TGs), and low-density lipids (LDLs), increased significantly (p < 0.05), but high-density lipid (HDL) decreased significantly (p < 0.05) in the diabetic controls compared to those in the normal controls. On the other hand, TC, TG, and LDL decreased significantly (p < 0.05), while HDL increased significantly (p < 0.05) in the diabetic rats treated with PCMOS, PCMAX, and glibenclamide. 3.6.1. Renal Function TP in the diabetic controls decreased significantly (p < 0.05) compared to that in the normal controls. In contrast, it increased significantly (p < 0.05) in the diabetic rats treated with PCMOS, PCMAX, and glibenclamide and was similar to that in the normal controls. However, BUN and creatinine in the diabetic controls and diabetic rats treated with PCMOS, PCMAX, and glibenclamide were not different and were not different from those in the normal controls. 3.6.2. Hepatic Function AST in the diabetic controls increased significantly (p < 0.05) compared to that in the normal controls. However, it decreased significantly (p < 0.05) in the diabetic rats treated with PCMOS, PCMAX, and glibenclamide and was not different from that in the normal controls. Changes in ALT were not found among different groups of rats. ALP in the diabetic controls increased significantly (p < 0.05) but decreased significantly (p < 0.05) in the diabetic rats treated with PCMOS, PCMAX, and glibenclamide compared to that in the diabetic controls. Interestingly, ALP in the diabetic rats treated with PCMOS, PCMAX, and glibenclamide was comparable to that in the normal controls. 3.7. Histological Observation Histological observations revealed that the pancreatic tissues of the diabetic controls experienced morphological changes with injury and death of pancreatic β cells leading to a decrease in the size of islets of Langerhans (143.74 ± 2.11µ; Figure 1(b)) and the number of β cells (84.06 ± 2.02 cells/unit; Table 3) compared with the normal controls (222.03 ± 2.71µ; Figure 1(a) and 190.37 ± 7.84 cells/unit; Table 3). Surprisingly, PCMOS and PCMAX attenuated diabetes-induced pancreatic morphological changes by significantly increasing (p < 0.05) the size of islets of Langerhans and the number of β cells in the diabetic rats treated with PCMOS (210.46 ± 4.05µ; Figure 1(c) and 134.02 ± 4.11 cells/unit; Table 3) and in the diabetic rats treated with PCMAX (214.27 ± 4.49µ; Figure 1(d) and 162.34 ± 3.72 cells/unit; Table 3). However, they were not different from those in the diabetic rats treated with glibenclamide (209.80 ± 3.46µ; Figure 1(e) and 158.25 ± 9.11 cells/unit). 3.8. Determination of Antioxidant Activity The results of the determination of antioxidant activity of PCMOS and PCMAX are presented in Table 5. The DPPH assay revealed that PCMOS exhibited a scavenging DPPH radical less potent than PCMAX did with EC50 of 13.69 ± 0.45 vs. 8.03 ± 0.95 µg/mL, respectively. However, PCMOS and PCMAX possessed a relatively low antioxidant activity compared to ascorbic acid (0.01 ± 0.02 µg/mL); while using the FRAP assay, it was demonstrated that PCMOS exhibited less antioxidant activity by reducing Fe2+ than ECMAX did with 31.23 ± 3.15 vs. 42.67 ± 0.77 mMFe2+/g, respectively. PCMOS and PCMAX exhibited antioxidant activity as measured by the DPPH and FRAP assay in a concentration-dependent manner. PCMOS showed less TPC and TFC values than PCMAX with values of 5.27 ± 0.31 vs. 11.22 ± 0.19 mgGAE/g and 20.81 ± 0.09 vs. 55.08 ± 2.21 mgCE/g, respectively. 4. Discussion Streptozotocin (STZ) is one of the most commonly used substances to induce diabetes in rats. STZ selectively destroys pancreatic insulin-secreting β cells causing diabetes similar to type 2 diabetes in humans according to [23], and induction of diabetes with STZ was associated with the characteristic loss of body weight due to increased muscle wasting and loss of tissue proteins because protein and fat are broken down to provide energy instead of blood glucose [47]; therefore, the body weight in the STZ-induced diabetic rats (diabetic controls) in the present study decreased significantly. The results are consistent with the report by Baldi et al. who found that a pumpkin concentrate caused a significant decrease in body weight in diabetic control rats [48]. Oral administration of PCMOS and PCMAX at a dose of 500 mg/kg to the rats once a day for six weeks increased the body weight of the PCMOS and PCMAX-treated diabetic rats because the characteristics of PCMOS and PCMAX were consistent with the pumpkin concentrate preparation, which increased the body weight of diabetic rats [23], and a water-soluble polysaccharide from pumpkin significantly increased the body weight of diabetic rabbits [17]. The action of PCMOS and PCMAX to increase the body weight of diabetic rats is probably due to their hypoglycemic property, which increases the utilization of blood glucose and, in turn, prevents the breakdown of fat and protein to provide energy. STZ causes the destruction of the pancreatic insulin-secretingβ cells, which reduces insulin and, in turn, results in a rise in blood glucose concentration, i.e., hyperglycemia [49]; the extracts, especially PCMAX, significantly decreased the blood glucose levels in the diabetic rats. This indicates that PCMAX contains a hypoglycemic agent which is responsible for lowering blood glucose levels. The blood glucose level of the diabetic control rats was still high during the experimentation for six weeks. However, the haematological values except for the platelet in the diabetic control rats and diabetic rats treated with PCMOS and PCMAX did not alter compared to those in the normal controls. This indicates that PCMOS and PCMAX produce nontoxicity as judged by haematological values. Serum insulin levels were found to be increased in the diabetic rats treated with PCMOS and PCMAX. This result is in agreement with results for the alcoholic seed extract of C. maxima which significantly reduced the elevated fasting blood glucose level by increasing the pancreatic secretion of insulin from β cells of islets of Langerhans in STZ-induced diabetic albino Wistar rats [23]. Lipid profiles, including total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein (LDL), increased significantly. In contrast, the high-density lipoprotein (HDL) decreased significantly in the diabetic controls [50, 51]. In the present study, oral administration of PCMOS and PCMAX at a dose of 500 mg/kg to the diabetic rats once a day for six weeks significantly decreased TC, TG, and LDL levels but increased HDL levels in the treated diabetic rats. In agreement with the present data, there have been reports that the lipid profiles were changed to decrease total cholesterol, triglycerides, and LDL and increase HDL levels in the diabetic rats treated with pumpkin (C. maxima) at a dose of 400 mg/kg [52], and the administration of the pumpkin polysaccharide significantly lowered TC and TG in diabetic rabbits [17]. These results may be associated with the possible protective effect of the extract (mainly polysaccharides) on pancreatic β cells. In addition, these effects may be due to the low activity of cholesterol biosynthetic enzymes or the insignificant level of lipolysis under the control of insulin [53]. Moreover, in pumpkin seeds, unsaturated fatty acids, such as oleic acid and linoleic acid, can reduce cholesterol levels in rats [54]. These activities of PCMOS and PCMAX probably involve inhibiting the absorption of bile acids and cholesterol and enhancing the activity of LDL receptors [55]. PCMOS and PCMAX recovered TP and showed no effects on BUN as BUN in the diabetic controls, diabetic rats treated with PCMOS, PCMAX, and glibenclamide, and normal controls was not different. These results indicate the nontoxicity of PCMOS and PCMAX in renal function. AST and ALP increased in the diabetic controls, but they decreased in the diabetic rats treated with PCMOS and PCMAX, and the levels were close to those in the normal controls. In addition, ALT in all rats was not different. These results indicate that PCMOS and PCMAX can improve the pathological hepatic function resulting from STZ-induced diabetes. In the present study, histological observation revealed a difference in the mean diameter and the number of Langerhans islets and the number of pancreatic β cells between the diabetic controls and the normal controls. Decreasing the size of islets of Langerhans and the number of pancreatic β cells indicated the destruction of pancreatic tissues in diabetic rats. Aboulthana et al. reported that STZ caused inflammatory changes in pancreatic islets of diabetic rats. Consequently, this leads to atrophy in islands of the Langerhans cells associated with the vacillation of islet cells [56]. This might be due to the destruction of β cells and hence a decrease in pancreatic islets. This finding agrees with that of Sedigheh et al. who stated that histological analysis showed significant differences in the mean diameter and the number of Langerhans islets between the diabetic control group and the standard control group [57]. The mean diameter of islets in the diabetic group significantly decreased compared with that in the normal control group. Pancreatic β cells take up STZ via the GLUT 2 transporter, which leads to β-cell death by DNA fragmentation [58]. Due to the optical microscope images of islets of β cells of experimental animals, this suggests that the oral administration of PCMOS and PCMAX was potentially effective after STZ damage. The histopathological investigation showed that PCMOS and PCMAX could prevent pancreatic β-cell damage and increase the size and number of islets of Langerhans, leading to an increase in insulin levels. It has been reported that the fruit flesh powder of C. maxima significantly improved blood glucose and insulin levels and healed Langerhans islets by increasing the number and size of Langerhans islets in STZ-induced diabetic rats, indicating the effects of pumpkin powder on the repair and restoration of pancreatic tissues [22], and the methanol extract of aerial parts of C maxima altered the histological profiles of the pancreas of the STZ-induced diabetic albino Wistar rats to match those in the normal controls [25] more closely. The activity of PCMOS and PCMAX was in agreement with that of the methanol extract of C. maxima which attenuated diabetes-induced pancreatic injury in STZ-induced diabetic rats [26]. Administration of antioxidants to diabetic rats significantly increased the number of β cells [59]. Antioxidant compounds could increase the number of pancreatic β cells by enhancing the repair and restoration of these cells. Moreover, flavonoids could protect DNA from oxidative damage to lessen the problem in β cells [60–62]. According to these findings, (1) the phytochemical investigation of pumpkins reveals the presence of polysaccharides [15], (2) chemicals from pumpkin fruit pulp that are hypoglycemic include polysaccharides [63], (3) polysaccharides cause a significant decrease in the blood glucose of STZ-induced diabetic rats [64], (4) powdered pumpkin has hypoglycemic activity in alloxan-induced diabetic rats [58], which is due to polysaccharide components [15, 28, 58, 65], (5) protein-bound polysaccharides from the fruit of pumpkin (C. moschata) could decrease blood glucose levels [29], and (6) the polysaccharide is the main chemical in extracts, with 33.41% in PCMOS and 36.99% in PCMAX. These suggest that the hypoglycemic activity of PCMOS and PCMAX could be partly due to polysaccharide content. Previous studies using high-performance liquid chromatography (HPLC) analysis found the content of free sugars and polysaccharides in C. maxima fruits [66]. In addition, C. moschata polysaccharide possessed significant cytoprotective effects on diabetes and antioxidative activity [32], flavonoid extracted from Cucurbitaceae possessed hypoglycemic activity in diabetic rats [67], and oral administration of pumpkin seed extracts produced a significant antidiabetic effect in controlling the blood glucose level, possibly due to flavonoids [22]. Thus, the extracts were significantly antidiabetic, and the antioxidant effect correlates with the presence of the components mentioned. Based on the presence of total phenolic (TPC) and total flavonoid (TFC) content in PCMOS and PCMAX, PCMOS and PCMAX exhibited significant antidiabetic activity, almost the same as glibenclamide, an antidiabetic drug; the mechanism of action on antidiabetic activity of PCMOS and PCMAX may be due to the polysaccharide, phenolic, and flavonoid content improving STZ-induced damage to pancreatic islets of Langerhans and stimulated serum insulin secretion from pancreatic β cells resulting in a reduction of blood glucose. The DPPH scavenging and ferric reducing activity assay revealed the antioxidant activity of PCMOS and PCMAX, and PCMOS exhibited less potent antioxidant activity than PCMAX. However, they showed a relatively low activity compared to ascorbic acid, a reference agent. Because phenolic and flavonoid compounds are responsible for antioxidant activity in plants [68], the phenolic compound present in plants possesses hydroxyl groups with radical scavenging activity; antioxidants, in interaction with DPPH, either transfer an electron or a hydrogen atom to DPPH [69]. The methanol extract from aerial parts of C. maxima exhibits potent antioxidant activity with free radical scavenging activity equivalent to BHT, and the antioxidant property may be due to phenolic and flavonoid contents [25]. Therefore, the antioxidant activity of PCMOS and PCMAX in the present study was partly due to total phenolic and flavonoid contents. Nevertheless, the factors which involve the antioxidant effect of C. moschata showed high genetic variability for synthesising phenolic compounds, carotenoids, and antioxidant activity [70]. While the ABTS radical scavenging activity of pumpkin tended to increase according to the level of pumpkin leaf powder [71], the fruit acetone extract has an antioxidant effect of being higher in C. maxima lines than in C. moschata lines [14], and the antioxidant activity is more affected by the type of cultivar than by the pumpkin species [13]. Furthermore, numerous studies have shown that administering antioxidants to diabetic rats increases the number of β cells [42, 59]. Therefore, the pancreatic protective effect and its hypoglycemic properties should be attributable, in part, to the antioxidant activity of these two fruit pulps [22]. 5. Conclusions The fruit pulp extracts from C. moschata (PCMOS) and C. maxima (PCMAX) exhibit both antidiabetic activity in STZ-induced diabetic rats and antioxidant activity. The extracts display the antidiabetic activity by increasing the β-cell number and size of islets of Langerhans which lead to reducing blood glucose levels in the treated diabetic rats. They exert the antioxidant activity by DPPH scavenging and ferric reducing activity. PCMAX exhibits more potent activities than PCMOS which may result from PCMAX giving more polysaccharides and total phenolic and flavonoid contents. In the present study, a single dose (500 mg/kg·b.w.) of the extracts was used for the antidiabetic activity assessment. In further studies, various doses of the extracts should be employed to determine whether the activity is in a dose-dependent manner. Acknowledgments The authors acknowledge the support provided by the Development Research Division, Mahasarakham University, the Science Achievement Scholarship of Thailand, and the National Research Council of Thailand. Data Availability The data that support the findings of this study are available from the corresponding author upon request. Conflicts of Interest The authors declare that they have no conflicts of interest. Figure 1 Representative light micrographs of islets of Langerhans in normal controls (a), diabetic controls (b), diabetic rats treated with PCMOS (c), diabetic rats treated with PCMAX (d), and diabetic rats treated with glibenclamide (e). Table 1 Body weight of normal controls, diabetic controls, diabetic rats treated with PCMOS, diabetic rats treated with PCMAX, and diabetic rats treated with glibenclamide. Groups Body weight (g) Initial weight Final weight Normal controls 244.63 ± 7.84a 361.33 ± 10.95b DM 236.10 ± 4.67a 301.56 ± 11.12a DM + PCMOS 238.32 ± 7.18a 354.16 ± 7.44b DM + PCMAX 240.10 ± 8.09a 359.66 ± 7.74b DM + Glib 238.16 ± 9.15a 354.16 ± 8.96b Values are expressed as means ± S.E.M, n = 6 rats in each group. There was no significant difference between means that have the same alphabetical superscript letter in the same column (p < 0.05). Statistical analysis was carried out using one-way ANOVA followed by Duncan's test. DM = diabetic rats; Glib = glibenclamide. Table 2 Haematological values of normal controls, diabetic controls, diabetic rats treated with PCMOS, diabetic rats treated with PCMAX, and diabetic rats treated with glibenclamide. Groups Haematological values RBC (×106 cells/mm3) WBC (×103 cells/mm3) Hb (g/dl) Hct (%) Neu (%) Lym (%) Mono (%) Plt (×103 cells/mm3) Normal controls 9.51 ± 0.12a 7.65 ± 3.45a 16.83 ± 0.31a 50.28 ± 0.59a 11.33 ± 0.49a 82.33 ± 0.49a 4.83 ± 0.70a 7.6.45 ± 2.26a DM 9.32 ± 0.19a 5.83 ± 1.38a 16.45 ± 0.91a 48.78 ± 1.03a 13.33 ± 1.22a 80.83 ± 1.24a 4.83 ± 0.60a 9.03 ± 1.12ab DM + PCMOS 9.71 ± 0.15a 8.90 ± 2.22a 16.86 ± 0.67a 49.48 ± 1.17a 15.00 ± 1.93a 80.00 ± 2.69a 3.66 ± 0.84a 9.26 ± 1.23ab DM + PCMAX 9.80 ± 0.17a 8.10 ± 2.31a 16.80 ± 0.51a 48.71 ± 0.83a 13.16 ± 1.79a 82.00 ± 1.59a 3.33 ± 0.80a 9.69 ± 1.34b DM + Glib 9.80 ± 0.08a 6.90 ± 2.12a 16.80 ± 0.72a 48.58 ± 1.21a 10.50 ± 1.74a 85.16 ± 1.51a 3.33 ± 0.33a 8.85 ± 1.51ab Values are expressed as means ± S.E.M, n = 6 rats in each group. There was a significant difference between means that have the different superscript letters in the same column (p < 0.05). Statistical analysis was carried out using one-way ANOVA followed by Duncan's test. DM = diabetic rats; Glib = glibenclamide; RBC = red blood cell; WBC = white blood cell; Hb = hemoglobin; Hct = hematocrit; Neu = neutrophil; Lym = lymphocyte; Mono = monocyte; Plt = platelet. Table 3 Fasting blood glucose, serum insulin level, number of β cells, and size of islets of Langerhans from normal controls, diabetic controls, diabetic rats treated with PCMOS, diabetic rats treated with PCMAX, and diabetic rats treated with glibenclamide. Parameters Groups Normal controls DM DM + PCMOS DM + PCMAX DM + Glib FBG (mg/dl) 83.07 ± 11.47a 186.66 ± 15.70c 102.16 ± 11.20b 96.00 ± 13.05b 96.6612.32b Serum insulin (µIU/mL) 23.88 ± 1.38c 12.14 ± 0.34a 13.00 ± 0.20a 16.64 ± 3.20b 24.80 ± 0.50c Number of β cells (cells/unit) 190.37 ± 7.84d 84.06 ± 2.02a 134.02 ± 4.11b 162.34 ± 3.72c 158.25 ± 9.11c Size of islets (micron) 222.03 ± 2.71bc 143.74 ± 2.11a 210.46 ± 4.05b 214.27 ± 4.49bc 209.80 ± 3.46b Values are expressed as means ± S.E.M, n = 6 rats in each group. There was a significant difference between means that have the different superscript letters in the same row (p < 0.05). Statistical analysis was carried out using one-way ANOVA followed by Duncan's test. DM = diabetic rats; Glib = glibenclamide; FBG = fasting blood glucose. Table 4 Biochemical values for determination of lipid profiles, renal function, and hepatic function in normal controls, diabetic controls, diabetic rats treated with PCMOS, diabetic rats treated with PCMAX, and diabetic rats treated with glibenclamide. Biochemical values Normal controls DM DM + PCMOS DM + PCMAX DM + Glib Lipid profiles           CHO (mg/dl) 62.08 ± 3.5a 77.62 ± 5.03b 75.81 ± 5.01b 74.82 ± 2.34ab 69.65 ± 5.20ab TG (mg/dl) 128.37 ± 4.52bc 121.33 ± 1.14bc 109.05 ± 2.09a 106.61 ± 1.53a 117.04 ± 2.24bc LDL (mg/dl) 15.17 ± 2.16a 21.53 ± 1.62b 18.34 ± 1.67ab 17.83 ± 2.25ab 21.82 ± 3.07b HDL (mg/dl) 60.86 ± 2.91b 49.52 ± 4.37a 56.57 ± 2.36ab 57.09 ± 3.22ab 53.64 ± 3.41ab Biochemical parameters           Renal function           TP (g/dl) 6.66 ± 0.82b 5.61 ± 0.34a 6.75 ± 0.42b 6.48 ± 0.63b 6.07 ± 0.51ab BUN (mg/dl) 16.04 ± 1.33a 15.04 ± 1.47a 18.02 ± 2.34a 20.63 ± 2.90a 18.37 ± 2.09a Crea (mg/dl) 0.58 ± 0.18a 0.55 ± 0.15a 0.53 ± 0.11a 0.53 ± 0.10a 0.53 ± 0.14a Hepatic function           AST (U/L) 126.16 ± 3.32a 148.53 ± 6.08b 122.87 ± 2.03a 130.16 ± 0.13a 133.64 ± 1.09a ALT (U/L) 43.07 ± 2.42a 50.81 ± 3.03a 46.09 ± 6.05a 43.32 ± 6.08a 48.20 ± 3.41a ALP (U/L) 100.19 ± 0.17ab 122.06 ± 3.17c 104.08 ± 2.13b 95.28 ± 2.07ab 93.80 ± 3.09a Values are expressed as means ± S.E.M, n = 6 rats in each group. There was a significant difference between means that have the different superscript letters in the same row (p < 0.05). Statistical analysis was carried out using one-way ANOVA followed by Duncan's test. DM = diabetic rats; Glib = glibenclamide; TG = triglyceride; CHO = cholesterol; LDL = low-density lipoprotein; HDL = high-density lipoprotein; TP = total protein; BUN = blood urea nitrogen; Crea = creatinine; AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase. Table 5 Antioxidant activity of PCMOS and PCMAX using DPPH assay, FRAP assay, total phenolic content (TPC), and total flavonoid content (TFC). Samples DPPH assay EC50 (µg/ml) FRAP assay (mMFe2+/g) TPC (mgGAE/g) TFC (mgCE/g) PCMOS 13.69 ± 0.45c 31.23 ± 3.15a 5.27 ± 0.31a 20.81 ± 0.09a PCMAX 8.03 ± 0.95b 42.67 ± 0.77b 11.22 ± 0.19b 55.08 ± 2.21b Ascorbic acid 0.01 ± 0.02a — — — Values are expressed as means ± S.E.M, n = 3 replications. There was a significant difference between means that have the different superscript letters in the same column (p ≤ 0.05). Statistical analysis was carried out using one-way ANOVA followed by Duncan's test. ==== Refs 1 Sancheti S. Sancheti S. Seo S. Y. Chaenomeles sinensis: a potent α-and β-glucosidase inhibitor American Journal of Pharmacology and Toxicology 2009 4 1 8 11 10.3844/ajptsp.2009.8.11 2-s2.0-65549133341 2 Marbun N. Comparison of blood glucose levels decrease effectiveness of pumpkin flesh and seeds toward diabetic mice 2017 Medan, Indonesia University of Sumatera Utara 1 106 Ph.D Thesis 3 Parthasarathy R. Illavarasan R. Karrunakaran C. M. Antidabetic activity of Thespesia populnea bark and leaf extract against streptozotocin-induced diabetic rats International Journal of PharmTech Research 2009 1 4 1069 1072 4 Krisanapun C. Lee S. H. Peungvicha P. Temsiririrkkul R. Baek S. J. Antidiabetic activities of Abuilon indicum (L.) sweet are mediated by enhancement of adipocyte differentiation and activation of the GLUT1 promoter Evidence-based Complementary and Alternative Medicine 2011 2011 9 167684 10.1093/ecam/neq004 2-s2.0-79953324777 5 World Health Organization Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia 2006 Geneva, Switzerland World Health Organization 6 Jia W. Gao W. Tang L. Antidiabetic herbal drugs officially approved in China Phytotherapy Research 2003 17 10 1127 1134 10.1002/ptr.1398 2-s2.0-0346095665 14669243 7 Dhiman K. Gupta A. Sharma D. K. Gill N. Goyal A. A review on the medicinally important plants of the family Cucurbitaceae Asian Journal of Clinical Nutrition 2011 4 1 16 26 10.3923/ajcn.2012.16.26 2-s2.0-84863403518 8 Oyeleke A. W. Oluwajuyitan D. T. Oluwamukomi O. M. Enujiugha N. V. Amino acid profile, functional properties and in-vitro antioxidant capacity of Cucurbita maxima and Cucurbita mixta fruit pulps and seeds European Journal of Nutrition and Food Safety 2019 10 4 224 241 10.9734/ejnfs/2019/v10i430117 9 Kirtikar K. R. Basu B. D. Indian Medicinal Plants 2003 Dehradun, India Oriental Enterprises 10 Al-Shaheen S. J. A. Kaskoos R. A. Hamad K. J. Ahamad J. In-vitro antioxidant and α-amylase inhibition activity of Cucurbita maxima Journal of Pharmacognosy and Phytochemistry 2013 2 2 121 124 11 Dar A. H. Sofi S. A. Rafiq S. Pumpkin the functional and therapeutic ingredient: a review International Journal of Food Sciences and Nutrition 2017 2 6 165 170 12 Behera T. K. Sureja A. K. Islam S. Munshi A. D. Sidhu A. S. Wang Y. Behera T. K. Kole C. Minor cucurbits Genetics, Genomics and Breeding of Cucurbits 2012 New York, NY, USA Science Publishers 13 Kulczyński B. Sidor A. Gramza-Michałowska A. Antioxidant potential of phytochemicals in pumpkin varieties belonging to Cucurbita moschata and Cucurbita pepo species CYTA-Journal of Food 2020 18 1 472 484 10.1080/19476337.2020.1778092 14 Abbas H. M. K. Huang H. X. Huang W. J. Evaluation of metabolites and antioxidant activity in pumpkin species Natural Product Communications 2020 15 4 1934578X2092098 10.1177/1934578x20920983 15 Caili F. Huan S. Quanhong L. A review on pharmacological activities and utilization technologies of pumpkin Plant Foods for Human Nutrition 2006 61 2 70 77 10.1007/s11130-006-0016-6 2-s2.0-33746189349 16 Dabaghian F. H. Kamalinejad M. Shojaei A. Fard M. A. Presenting antidiabetic plants in Iranian traditional medicine Journal of Diabetes and Endocrinology 2012 3 5 61 67 17 Zhang Y. Chen P. Zhang Y. Effects of polysaccharide from pumpkin on biochemical indicator and pancreatic tissue of the diabetic rabbits International Journal of Biological Macromolecules 2013 62 574 581 10.1016/j.ijbiomac.2013.09.044 2-s2.0-84886850308 24095662 18 Simpson R. Morris G. A. The anti-diabetic potential of polysaccharides extracted from members of the Cucurbit family: a review Bioactive Carbohydrates and Dietary Fibre 2014 3 2 106 114 10.1016/j.bcdf.2014.03.003 2-s2.0-84907422146 19 Chen Z. Wang X. Jie Y. Huang C. Zhang G. Study on Hypoglycemia and Hypotension Function of Pumpkin Powder on Human 1994 Nanchang, China Jiangxi University of Traditional Chinese Medicine 20 Lal V. K. Gupta P. P. Pandey A. Tripathi P. Effect of hydro-alcoholic extract of Cucurbita maxima, fruit juice and Glibenclamide on blood glucose in diabetic rats American Journal of Pharmacology and Toxicology 2011 6 3 84 87 10.3844/ajptsp.2011.84.87 21 Mahmoodpoor A. Medghalchi M. Nazemiyeh H. Asgharian P. Shadvar K. Hamishehkar H. Effect of Cucurbita maxima on control of blood glucose in diabetic critically Ill patients Advanced Pharmaceutical Bulletin 2018 8 2 347 351 10.15171/apb.2018.040 2-s2.0-85048896288 30023337 22 Alyae M. S. G. Ameliorative activity of pumpkin (Cucurbita maxima) fruit and seeds powders on diabetic, oxidative and pancreatic status in rats International Journal of Biochemistry Research and Review 2019 26 2 1 9 23 Sharma A. Sharma A. K. Chand T. Khardiya M. Yadav K. C. Antidiabetic and antihyperlipidemic activity of Cucurbita maxima Duchense (pumpkin) seeds on streptozotocin induced diabetic rats Journal of Pharmacognosy and Phytochemistry 2013 1 6 108 116 24 Kushawaha D. K. Yadav M. Chatterji S. Srivastava A. K. Watal G. α- Amylase and α-glucosidase inhibitory activity assessment of Cucurbita maximaseeds-A LIBS based study International Journal of Phytomedicine 2016 8 3 312 318 10.5138/09750185.1906 2-s2.0-85019508470 25 Saha P. Mazumder U. K. Haldar P. K. Vitro antioxidant activity of Cucurbita maxima aerial parts Free Radicals and Antioxidants 2011 1 1 42 48 10.5530/ax.2011.1.8 26 Atta A. H. Saad S. A. Atta S. A. Cucumis sativus and Cucurbita maxima extract attenuate diabetes-induced hepatic and pancreatic injury in a rat model Journal of Physiology and Pharmacology 2020 71 4 507 518 10.26402/jpp.2020.4.06 27 Zhang Y. J. Study on the hypoglycemic effects and extraction and analysis of pumpkin polysaccharide Journal China Jiliang University 2004 15 3 238 241 28 Wang S. Lu A. Zhang L. Extraction and purification of pumpkin polysaccharides and their hypoglycemic effect International Journal of Biological Macromolecules 2017 98 182 187 10.1016/j.ijbiomac.2017.01.114 2-s2.0-85011575211 28153462 29 Quanhong L. Caili F. Yukui R. Guanghui H. U. Tongyi C. Effects of protein-bound polysaccharide isolated from pumpkin on insulin in diabetic rats Plant Foods for Human Nutrition 2005 60 1 13 16 10.1007/s11130-005-2536-x 2-s2.0-20144363468 15898354 30 Guillon F. Champ M. Structural and physical properties of dietary fibres, and consequences of processing on human physiology Food Research International 2000 33 3-4 233 245 10.1016/s0963-9969(00)00038-7 2-s2.0-0034064509 31 Peiretti P. G. Meineri G. Gai F. Longato E. Amarowicz R. Antioxidative activities and phenolic compounds of pumpkin (Cucurbita pepo) seeds and amaranth (Amaranthus caudatus) grain extracts Natural Product Research 2017 31 18 2178 2182 10.1080/14786419.2017.1278597 2-s2.0-85010676769 28114838 32 Yang X. Zhao Y. Lv Y. Chemical Composition and antioxidant activity of an acidic polysaccharide extracted from Cucurbita moschata Duchesne ex Poiret Journal of Agricultural and Food Chemistry 2007 55 12 4684 4690 10.1021/jf070241r 2-s2.0-34250741308 17511465 33 Nara K. Yamaguchi A. Maeda N. Koga H. Antioxidative activity of water soluble polysaccharide in pumpkin fruits (Cucurbita maxima Duchense) Bioscience Biotechnology and Biochemistry 2009 73 6 1416 1418 10.1271/bbb.80529 2-s2.0-67949091252 19502750 34 Mokhtar M. Bouamar S. Di Lorenzo A. Temporini C. Daglia M. Riazi A. The influence of ripeness on the phenolic content, antioxidant and antimicrobial activities of pumpkins (Cucurbita moschata duchesne) Molecules 2021 26 12 p. 3623 10.3390/molecules26123623 35 Govindani H. Dey A. Deb L. Protective role of methanolic and aqueous extracts of Cucurbita moschata Linn Fruits in Inflammation and Drug Induced Gastric Ulcer in Wister Rats 2012 4 4 1758 1765 36 Indrianingsih A. W. Rosyida V. T. Apriyana W. Comparisons of antioxidant activities of two varieties of pumpkin (Cucurbita moschata and Cucurbita maxima) extracts IOP Conference Series: Earth and Environmental Science 2019 251 012021 10.1088/1755-1315/251/1/012021 2-s2.0-85064871965 37 Kim M. J. Hong C. O. Nam M. H. Lee K. W. Antioxidant effects and physiological activities of pumpkin (Cucurbita moschata Duch.) extract from different aerial parts Korean Journal of Food Science and Technology 2011 43 2 195 199 10.9721/kjfst.2011.43.2.195 2-s2.0-79959366613 38 Promsakha na Sakon Nakhon P. Jangchud K. Jangchud A. Prinyawiwatkul W. Comparisons of physicochemical properties and antioxidant activities among pumpkin (Cucurbita moschata L.) flour and isolated starches from fresh pumpkin or flour International Journal of Food Science and Technology 2017 52 11 2436 2444 10.1111/ijfs.13528 2-s2.0-85026660706 39 Liangpanth T. Sasanatayart R. Effect of thermal treatments on antioxidant properties of pumpkin flesh and their stability during in-vitro gastrointestinal digestion Food and Applied Bioscience Journal 2019 7 3 118 130 40 Talubmook C. Forrest A. Parsons M. Streptozotocin-induced diabetes modulates presynaptic and postsynaptic function in the rat ileum European Journal of Pharmacology 2003 469 1-3 153 158 10.1016/s0014-2999(03)01722-9 2-s2.0-0038730508 12782197 41 Padee P. Nualkaew S. Talubmook C. Sakuljaitrong S. Hypoglycemic effect of a leaf extract of Pseuderanthemum palatiferum (Nees) Radlk. in normal and streptozotocin-induced diabetic rats Journal of Ethnopharmacology 2010 132 2 491 496 10.1016/j.jep.2010.07.056 2-s2.0-78049402201 20813181 42 Berraaouan A. Abderrahim Z. Hassane M. Abdelkhaleq L. Mohammed A. Mohamed B. Evaluation of protective effect of cactus pear seed oil (Opuntia ficus-indica L. MILL.) against alloxan- induced diabetes in mice Asian Pacific Journal of Tropical Medicine 2015 8 7 532 537 10.1016/j.apjtm.2015.06.013 2-s2.0-84938981001 26276283 43 Nakornriab M. Krasaetep J. Phytochemicals and antioxidant activity of Thai rice flowers Journal of Food Health and Bioenvironmental Science 2018 11 1 97 111 44 Zolfaghari B. Movahedian A. Mirshekari M. Antioxidant effects of hydroalcoholic and polyphenolic extracts of Peucedanum pastinacifolium Boiss. and Hausskn Research in Pharmaceutical Sciences 2016 11 5 405 411 10.4103/1735-5362.192492 2-s2.0-85014142246 27920823 45 Bonoli M. Verardo V. Marconi E. Caboni M. F. Antioxidant phenols in barley (Hordeum vulgare L.) flour: comparative spectrophotometric study among extraction methods of free and bound phenolic compounds Journal of Agricultural and Food Chemistry 2004 52 16 5195 5200 10.1021/jf040075c 2-s2.0-3843100618 15291496 46 Prasad K. N. Yang B. Dong X. Flavonoid contents and antioxidant activities from Cinnamomum species Innovative Food Science and Emerging Technologies 2009 10 4 627 632 10.1016/j.ifset.2009.05.009 2-s2.0-68949191025 47 Chatterjea M. N. Shinde R. Text Book of Medical Biochemistry 2002 New Delhi, India Jaypee brothers medical publishers 48 Baldi A. Choudhary N. Maru J. Joshi R. Effect of pumpkin concentrate on alloxan induced diabetic rats Journal of Global Pharma Technology 2010 2 10 24 27 49 Elsner M. Guldbakke B. Tiedge M. Munday R. Lenzen S. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin Diabetologia 2000 43 12 1528 1533 10.1007/s001250051564 2-s2.0-0034434893 11151762 50 Sheu W. H. Lee C. Y. Lin S. Y. Pei D. Chen Y. T. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with contained hyperlipidemia Metabolism 2021 50 335 359 10.1053/meta.2001.21026 2-s2.0-0035082925 51 Harrison D. Griendling K. Landmesser U. Hornig B. Drexler H. Role of oxidative stress in atherosclerosis The American Journal of Cardiology 2003 91 3 7A 11A 10.1016/s0002-9149(02)03144-2 2-s2.0-0037421492 52 Latha D. C. M. Kolavali Y. R. Evaluation of antihypertensive activity of cucurbita maxima European Journal of Pharmaceutical and Medical Research 2016 3 11 472 476 53 Ahmet B. Ezel U. Mine K. Meltem U. Ali I. Oktay S. H. Evaluation of salivary sialic acid level and Cu-Zn superoxide dismutase activity in type 1 diabetes mellitus Journal of Experimental Medicine 2000 192 219 255 10899908 54 Takada R. Saitoh M. Mori T. Dietary gamma linolenic acid-enriched oil reduces body fat content and induces liver enzyme activities relating to fatty acid beta oxidation in rats Journal of Nutrition 1994 124 4 469 474 10.1093/jn/124.4.469 8145067 55 Lecumberri E. Goya L. Mateos R. A diet rich in dietary fiber from cocoa improves lipid profile and reduces malondialdehyde in hypercholesterolemic rats Nutrition 2007 23 4 332 341 10.1016/j.nut.2007.01.013 2-s2.0-33947706755 17367998 56 Aboulthana W. M. El-Feky A. M. Ibrahim N. E. Sahu R. K. El-Sayed A. B. Evaluation of the pancreatoprotective effect of Nannochloropsis oculata extract against streptozotocin-induced diabetes in rats Journal of Applied Pharmaceutical Science 2018 8 6 046 058 57 Sedigheh A. Jamal M. S. Mahbubeh S. Hypoglycaemic and hypolipidemic effects of pumpkin (Cucurbita pepo L.) on alloxan-induced diabetic rats African Journal of Pharmacy and Pharmacology 2011 5 23 2620 2626 58 Ventura-Sobrevilla J. Boone-Villa V. D. Aguilar C. N. Effect of varying dose and administration of streptozotocin on blood sugar in male CD1 mice Proceedings of the Western Pharmacology Society 2011 54 5 9 22423571 59 Asgary S. Parkhideh S. Solhpour A. Madani H. Mahzouni P. Rahimi P. Effect of ethanolic extract of Juglans regia L. on blood sugar in diabetes-induced rats Journal of Medicinal Food 2008 11 3 533 538 10.1089/jmf.2007.0611 2-s2.0-52149100416 18800903 60 Mujic A. Grdovic N. Mujic I. Antioxidative effects of phenolic extracts from chestnut leaves, catkins and spiny burs in streptozotocin-treated rat pancreatic β-cells Food Chemistry 2011 125 3 841 849 10.1016/j.foodchem.2010.08.068 2-s2.0-78149407400 61 Kabbaoui M. E. Chda A. Mejrhit N. Antidiabetic effect of Thymus satureioides aqueous extract in streptozotocin-induced diabetic rats International Journal of Pharmacy and Pharmaceutical Sciences 2016 8 9 140 145 10.22159/ijpps.2016v8i9.12647 2-s2.0-84988622285 62 Bharathi T. R. Prakash H. S. Comparative evaluation of antidiabetic and antioxidant potency of different extracts obtained from Memecylon species International Journal of Pharmacy and Pharmaceutical Sciences 2017 9 2 187 191 10.22159/ijpps.2017v9i2.15695 63 Zhang Y. Yao H. Study on effect of hypoglycemia of different type pumpkin Journal of Chinese Food Science 2002 23 118 120 64 Ketwong B. Talubmook C. Effects of polysaccharide and triterpenoids from mushroom (Phellinus linteus) on blood glucose levels and hematological values in streptozotocin diabetic rats VRU Research and Development Journal 2010 5 17 25 65 Li J. Wang Y. Zhang D. Characterization and bioactivity of water-soluble polysaccharides from the fruit of pumpkin Journal of Food Agriculture and Environment 2010 8 2 237 241 66 Seroczynska A. Antczak A. Korytowska M. Evaluation of the selected forms of winter squash (Cucurbita maxima Duch.) Polish Journal of Agronomy 2014 16 69 73 67 Rauter A. P. Martins A. Borges C. Antihyperglycaemic and protective effects of flavonoids on streptozotocin-induced diabetic rats Phytotherapy Research 2010 24 2 133 138 10.1002/ptr.3017 2-s2.0-77953902140 68 Puravankara D. Boghra V. Sharma R. S. Effect of antioxidant principles isolated from mango (Mangifera indica L.) seed kernels on oxidative stability of buffalo ghee (butter-fat) Journal of the Science of Food and Agriculture 2000 80 4 522 526 10.1002/(sici)1097-0010(200003)80:4<522::aid-jsfa560>3.0.co;2-r 69 Chonoko U. G. Rufai A. B. Phytochemical screening and antibacterial activity of Cucurbita pepo against Staphylococcus aureus and Salmonella typhi Bayero Journal of Pure and Applied Sciences 2011 4 1 145 147 70 Priori D. Valduga E. Villela J. C. B. Characterization of bioactive compounds, antioxidant activity and minerals in landraces of pumpkin (Cucurbita moschata) cultivated in Southern Brazil Food Science and Technology 2016 37 1 33 40 10.1590/1678-457x.05016 2-s2.0-85013783457 71 Song K. Y. Hyeonbin O. Zhang Y. Joung K. Y. Kim Y. S. Effects of pumpkin (Cucurbita moschata duch.) leaf powder on quality characteristics, antioxidant activities, and retarding retrogradation by shelf-life of sponge cake Journal of the Korean Society of Food Science and Nutrition 2016 45 12 1792 1798 10.3746/jkfn.2016.45.12.1792 2-s2.0-85008895351